US Bancorp’s Cartesian Therapeutics RNAC Stock Holding History

US Bancorp’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$24K	–	4266
2022 Q3	$24K	Hold	500	–	–	﹤0.01%	2942
2022 Q2	$20K	Sell	500 -333	-40%	-$9.87K	﹤0.01%	3050
2022 Q1	$30K	Hold	833	–	–	﹤0.01%	2861
2021 Q4	$82K	Hold	833	–	–	﹤0.01%	2393
2021 Q3	$104K	Hold	833	–	–	﹤0.01%	2281
2021 Q2	$105K	Hold	833	–	–	﹤0.01%	2284
2021 Q1	$113K	Buy	+833	New	+$103K	﹤0.01%	2202

Other funds holding RNAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

US Bancorp's RNAC Position: Q4 2022 in Review

US Bancorp sold out of Cartesian Therapeutics (RNAC) in Q4 2022, closing a stake of 500 shares — an estimated $24K sold.

US Bancorp first reported a position in RNAC in Q1 2021 and held it in 7 quarters. The position peaked at $113K in Q1 2021. 84 funds tracked by Wall St. Rank hold RNAC as of Q4 2022.

US Bancorp reported no remaining Cartesian Therapeutics position as of Q4 2022 after selling out during the quarter.
US Bancorp sold 500 Cartesian Therapeutics shares in Q4 2022, an estimated $24K.
US Bancorp first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 7 quarters.
US Bancorp's Cartesian Therapeutics position peaked at $113K in Q1 2021.
84 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.